Haleon (LON:HLN) Shares Cross Below Two Hundred Day Moving Average – Here’s Why

Haleon plc (LON:HLN)’s stock price crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of GBX 360.62 and traded as low as GBX 310.50. Haleon shares last traded at GBX 316.60, with a volume of 1,048,323,188 shares changing hands.

More Haleon News

Here are the key news stories impacting Haleon this week:

• Positive Sentiment: Haleon approved a £500 million share repurchase program, equivalent to as much as 1.8% of outstanding shares. The buyback could support earnings per share and signals that management views the shares as undervalued. Haleon Q3 Revenue Rises; Trims Annual Revenue Growth Outlook; Launches £500 Mln Share Buyback
• Positive Sentiment: Jefferies reaffirmed its buy rating and set a GBX 400 price target, implying substantial upside from recent trading levels and providing some support for the stock. Jefferies reaffirms Haleon buy rating
• Neutral Sentiment: Deutsche Bank upgraded Haleon to hold but reduced its price target to GBX 310 from GBX 320. The change reflects a more balanced view rather than a strongly bullish signal. Deutsche Bank Haleon rating update
• Neutral Sentiment: Institutional positioning was mixed, with some major investors adding Haleon shares while others reduced holdings. These moves may influence sentiment but do not establish a clear near-term direction.
• Negative Sentiment: Haleon reported third-quarter organic revenue growth of 2.6%, below expectations, and cut its 2026 organic revenue growth outlook to about 2.5% from a previous 3%–5% range. Weak cough, cold and flu demand in North America, disruption to Centrum products in China, and a planned Brazil go-to-market change contributed to the downgrade. Haleon drops after Q3 sales miss and lower 2026 growth outlook

Wall Street Analyst Weigh In

Several research firms have commented on HLN. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 400 target price on shares of Haleon in a research note on Friday. Berenberg Bank upped their target price on Haleon from GBX 512 to GBX 514 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Deutsche Bank Aktiengesellschaft raised Haleon to a “hold” rating and decreased their price target for the stock from GBX 320 to GBX 310 in a research note on Friday. Finally, Royal Bank Of Canada upped their price objective on shares of Haleon from GBX 370 to GBX 390 and gave the company a “sector perform” rating in a research note on Tuesday, August 11th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of GBX 385.80.

Haleon Price Performance

The company has a 50 day simple moving average of GBX 352.97 and a 200 day simple moving average of GBX 360.40. The company has a market capitalization of £28.14 billion, a price-to-earnings ratio of 17.67, a price-to-earnings-growth ratio of 1.49 and a beta of 0.24. The company has a quick ratio of 0.93, a current ratio of 0.69 and a debt-to-equity ratio of 50.38.

Haleon (LON:HLN) last released its quarterly earnings data on Thursday, July 30th. The company reported GBX 8.60 earnings per share for the quarter. Haleon had a return on equity of 9.89% and a net margin of 14.55%. As a group, research analysts predict that Haleon plc will post 19.50 EPS for the current year.

Haleon declared that its Board of Directors has authorized a share repurchase plan on Thursday, October 29th that allows the company to buy back £500 million in shares. This buyback authorization allows the company to buy up to 1.8% of its shares through open market purchases. Share buyback plans are typically an indication that the company’s board of directors believes its stock is undervalued.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.